Introduction
Anogenital warts are a common problem among genitourinary medicine (GUM) clinic attenders. In the year 1994 alone there were 25 467 male patients who attended GUM departments in England with first presentation genital warts. ' An established first line treatment for anogenital warts is physician/nurse applied podophyllin, a non-standardised plant extract, up to three times per week. This is extremely intensive of clinical staff and patient time.
Commercial preparations of podophyllotoxin 05% (PDX 0 5%) (a purified derivative of podophyllin) (Condyline, Nycomed Ltd, Warticon, Perstopp Pharma) are available for the self treatment of anogenital warts and comparative studies have shown self treatment with PDX 0 5% to compare favourably with weekly clinic applied podophyllin 20%-40%.2A PDX 0.5% also has theoretical advantages when compared with podophyllin in that it is chemically defined, pure, and is stable with a defined shelf life but is considerably more expensive. Podophyllin 0.5-2.0% (PODO 0-5-2.0%) self applied in the same manner as PDX 0.5% has also been shown to be an effective treatment for penile warts.5 PODO 0-5-2-0% contains podophyllotoxin in the approximate range of 006%-0-25% but also contains other biologically active substances. 6 One small study has previously compared PODO 05% with PDX 0 5% and found no difference in outcome or side effects. 7 Potentially, PODO 0.5-2@0% offers an alternative to PDX 0.5% at a significant cost saving.
The primary aim of this study was to compare the efficacy and side effects of PDX 0.5%, PODO 05%, and PODO 2-0% for the self treatment of penile warts. It was designed as a three way randomised, double blind study. The If patients did not attend for review at week 5 they were sent a questionnaire and a stamped addressed envelope through the post asking for details of their response (side effects and whether warts healed completely) at the missed appointment time and for the return of their diary cards.
STATISTICS
The trial size was based on an expected 50% default/non-evaluable rate and a primary endpoint of whether warts were healed completely/not healed. Using the methods of Cohen8 it was estimated that 300 patients entered-that is, 150 evaluable patients, would give a 90% power to detect medium differences at the 5% level. A medium difference is defined as a difference between proportions ranging around 20%.
The results were entered onto a computer database and the analyses were carried out using SAS at the West Midlands Health Authority information department. Analysis was on an intention to treat basis. Before data analysis the report forms were reviewed for: patients with major violations of the treatment protocol-for example, those who never collected their treatment, used it for 1 day, or used it continuously; inappropriate recruitmentthat is, the exclusion/inclusion criteria had not been properly applied. These had all entries at follow up set to "unknown results". White, Billingham, Chapman, Drake, Jayaweera, Jones, et al In all, 126 (117 protocol eligible) patients who failed to attend for review at week 5 and for whom a postal address/permission to write had been given were sent postal questionnaires; 59 (55 protocol eligible) questionnaires were returned. None of the returned questionnaires said that treatment had been stopped because of side effects. These numbers were added to the week 5 examination figures to give an overall outcome as shown in table 3.
Only four patients reported stopping treatment due to side effects and all of these had 
Discussion
In common with other studies of genital wart treatment, we could not obtain any meaningful follow up data beyond 5 weeks. At 5 weeks this study was also affected by a larger default rate than expected. This is presumably because patients were largely unselected including for probable compliance. Only 105 (41%) of protocol eligible patients (33% of all entrants) had evaluable data as to whether they were cleared of warts on clinical examination at 5 weeks. The postal questionnaire, however, raised the number of patients to 158 (65% of protocol eligible, 50% of all entrants) on whom there was 5 weeks of cure rate data. In previous penile wart treatment studies comparing clinic applied podophyllin with PDX 0 5%, 5 week attendance rates have been in the order of 60%.24 These studies have, however, been open and included only selected protocol eligible, compliant patients in analyses which were not on an intention to treat basis. Caution must therefore be exercised when generalising findings of these studies to routine clinic attenders who may be less compliant not only with reattendance but also with their self application technique. These previous studies have also only had sufficient statistical power to detect large differences in outcome. An example of this is the study by Kinghorn et al. 4 This had 133 evaluable male patients at 5 weeks from six different centres and, by our calculation, had only a 72% power to exclude medium sized differences in cure rates at the 5% level. In comparison, our study had a double blind, randomised, intention to treat design, with a largely unselected patient group. If the patient questionnaire data are included then numbers are sufficient for the study to achieve its intended power. Whether side effects are sufficient for a treatment to stop is in any event a subjective decision by the patient. Whether warts have healed completely is also a subjective judgment and patients may be no more or less reliable witnesses than a nurse/doctor. We, therefore, consider the data from the questionnaire to be valid and useful. Also since the data from the questionnaire were evenly spread across the treatment groups any potential bias should be accounted for by the randomised, double blind design of the study. Although we would have wished for a lower default rate and better initial documentation we therefore consider that this study withstands comparison with previous studies.
We conclude therefore that for the self treatment of penile warts there are at worst only minor differences in efficacy between two formulations of podophyllin (PODO 0.5/ 2 0%) and 0 5% podophyllotoxin (PDX 0 5%). PODO 0.5 and 2-0% are also stable in their clinical effects for at least 3 In the financial year ending April 1995, 136 general practitioner prescriptions were dispensed for PDX 0.5% in Birmingham at a cost of £2024 (Dr S Chapman, personal communication). This is equivalent to £10 000 for the whole West Midlands Region and £ 100 000 per year nationally. As a small volume, unlicensed medication PODO 0-5% supplies are therefore unlikely to be available through community pharmacies. Ideally, all patients with genital warts should be encouraged to attend for full "STD screening" at their local genitourinary medicine departiment where, if PODO 0.5% is used for self treatment, they will receive a cheaper as well as more comprehensive treatment. In countries where the regulations on pharmacy manufacturing differ and where healthcare resources are limited PODO 0 5% may be an affordable treatment the use of which will free medical and nursing staff and improve patient compliance.
In this study, as in the previous studies of self applied PODO 0-5-2-0%, P hexandrum (emodii) derived podophyllin was used. No comment can therefore be made as to the safety and efficacy of self application of low strength podophyllin derived from P peltatum.
